Loading...
Market
Efficacy of clesrovimab in next large-scale trial for RSV prevention?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
More than 70% • 25%
Publication of trial results in scientific journals or Merck's official announcements
Story
Merck's Clesrovimab Shows 60.4% Efficacy in Preventing RSV in Infants
Oct 17, 2024, 10:02 PM
Merck's investigational monoclonal antibody, clesrovimab (MK-1654), has demonstrated significant efficacy in reducing the incidence of respiratory syncytial virus (RSV) disease and hospitalization in healthy preterm and full-term infants. The experimental therapy showed a 60.4% effectiveness in reducing RSV infections in infants, according to data released by Merck. This positive outcome paves the way for potential approval of clesrovimab as a preventative treatment for RSV in infants.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
Pfizer's ABRYSVO® • 25%
GSK's RSV vaccine • 25%
Moderna's RSV vaccine • 25%
Other • 25%
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%